Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.7 USD | +1.72% | -0.19% | -28.40% |
03-06 | Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating | MT |
02-29 | UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.40% | 608M | |
-18.56% | 8.35B | |
+45.10% | 3.58B | |
-8.06% | 2.47B | |
-38.71% | 2.46B | |
-7.96% | 2.36B | |
-13.72% | 1.78B | |
-19.73% | 1.53B | |
-40.78% | 1.21B | |
+8.32% | 1.12B |
- Stock Market
- Equities
- FLGT Stock
- News Fulgent Genetics, Inc.
- Fulgent Genetics Reports Higher Q3 Non-GAAP EPS as Revenue More Than Doubles, Lifts 2021 Revenue Guidance